Magrilan

Fluoxetine, the active ingredient in Magrilan, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral tablet for oral use. It is prescribed to manage major depressive disorder and several related psychiatric conditions in adult patients. The medication works by increasing serotonin availability in the brain, which can improve mood, anxiety and eating behaviours.

GNH USA supplies Magrilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Fluoxetine is used in several psychiatric disorders that involve dysregulated serotonin pathways. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Obsessive‑compulsive disorder: lessens intrusive thoughts and compulsive behaviours. - Panic disorder: decreases frequency and severity of panic attacks. - Bulimia nervosa: helps reduce binge‑eating episodes and purging behaviours. - Premenstrual dysphoric disorder: alleviates mood swings and physical symptoms associated with the menstrual cycle.

Fluoxetine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset, especially at treatment initiation. - Insomnia: difficulty falling or staying asleep. - Headache: transient cranial discomfort. - Sexual dysfunction: decreased libido or delayed orgasm. - Dry mouth: reduced salivation causing discomfort. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of suicidal ideation, particularly in young adults. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and muscle rigidity. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing fluoxetine, clinicians should consider several safety measures and patient‑specific factors. - Assess psychiatric history: evaluate risk of suicidal ideation before and during therapy. - Monitor for drug interactions: review concomitant serotonergic agents to avoid serotonin syndrome. - Check hepatic function: adjust use in patients with liver impairment. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Pregnancy and lactation: discuss potential risks with the prescriber. - Store at ambient temperature: keep in original container, protect from moisture and light.

Fluoxetine interacts with several medicines; understanding the level of interaction guides safe co‑administration.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a 14‑day washout is required. - Tricyclic antidepressants: increased plasma levels may cause cardiotoxicity. - Thioridazine: can precipitate QT prolongation and arrhythmias.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened bleeding risk. - Warfarin: fluoxetine may enhance anticoagulant effect, requiring INR monitoring. - Carbamazepine: may reduce fluoxetine concentrations, diminishing efficacy. - Bupropion: may increase risk of seizures when combined.